Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05387031Recruiting

Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease

Role: collaborator

NCT06709885Phase 2Recruiting

HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer

Role: collaborator

NCT04971070Completed

Analysis of Related Risk Factors of Hypoglycemia Consciousness Disorder

Role: lead

NCT04999722Not ApplicableUnknown

Establishment and Preliminary Evaluation of Digital Three Level Linkage Whole Process Diabetes Management System

Role: lead

All 4 trials loaded